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A vital step in growth factor–driven angiogenesis is the
 
coordinated engagement of endothelial integrins with the
extracellular matrix. The molecular mechanisms that
partner growth factors and integrins are being elucidated,
revealing an intricate interaction of surface receptors and
their signaling pathways.
 
Blood vessel formation is a dynamic process that involves inter-
 
actions between soluble mediators, adhesive substrates, and
endothelial cell surface receptors. Endothelial cell activation is a
necessary first step in angiogenesis, which triggers the recruit-
ment of smooth muscle cells and pericytes to newly formed
 
vessels. Two growth factor families activate this initiating
pathway in angiogenesis, the vascular endothelial growth factors
(VEGFs)* and fibroblast growth factors (FGFs) (for review see
Cross and Claesson-Welsh, 2001). VEGF-A, a factor that was
initially identified based on its ability to increase vascular
permeability and endothelial cell proliferation, is required for
angiogenesis during development and is a necessary stimulus for
 
hypoxia-induced angiogenesis. Four alternatively spliced
isoforms of VEGF-A exist that bind two receptor tyrosine
kinases,  VEGF receptor (VEGFR)-1 (Flt-1) and VEGFR-2
(Flk-1/KDR), on the surface of endothelial cells. The FGF
family is even more fecund, consisting of at least 20 members
that act on four separate receptors. Binding of VEGFs and
FGFs to their respective receptors triggers receptor tyrosine
phosphorylation followed by recruitment of intracellular
 
adaptor proteins and activation of signaling molecules (Fig. 1).
Through alterations in lipid metabolism, intracellular calcium
levels, and protein kinase and phosphatase activities, growth
factors elicit the pleiotrophic events necessary for new vessels
to sprout from preexisting ones.
Endothelial cell migration, proliferation, and the formation
of new lumen during angiogenesis require coordinated inter-
actions with the extracellular matrix (ECM). Growth factors
regulate these interactions, in part, by stimulating the secretion
of enzymes that degrade and alter ECM. Endothelial cell
adhesion molecules, such as the integrins, are also required
to coordinate interactions with the ECM. Integrins are
heterodimeric cell surface adhesion receptors that mediate
cell–cell and cell–ECM interactions and control cell migration,
 
differentiation, proliferation, and survival by generating
intracellular signals similar to those evoked by growth factors
(for review see Aplin et al., 1998). Two lines of evidence
 
suggest that endothelial 
 
 
 
V integrins in particular play a key
role in regulating angiogenesis. First, exogenously administered
 
antibody and small molecule inhibitors of 
 
 
 
V integrins
decrease or prevent angiogenesis of tumors, retinal vessels,
skin, and arthritic joints in a wide variety of animal and
experimental models. Second, 
 
 
 
V integrins appear to serve
as cellular receptors for several endogenous pro- and anti-
angiogenic proteins. In this mini-review, we examine recent
insights derived from studies of the integrin–growth factor
receptor nexus that help to understand how convergent and
divergent signaling pathways mediate angiogenic events. We
also consider studies which indicate that angiogenic integrins
serve as a crucial switch to regulate endothelial cell survival
and destruction.
 
Distinct angiogenic pathways as defined by specific 
growth factor–integrin pairs
 
The discovery by Cheresh and coworkers that antagonists
 
specific for 
 
 
 
V
 
 
 
3 or 
 
 
 
V
 
 
 
5 selectively block angiogenesis
induced by bFGF and VEGF, respectively, provided some
of the first support for a role of 
 
 
 
V integrins in angiogenesis
 
and led them to postulate the existence of two separate
angiogenic pathways (Friedlander et al., 1995). They observed
 
that antibody antagonists of 
 
 
 
V
 
 
 
3 abolished basic FGF
 
(bFGF)- and tumor necrosis factor 
 
 
 
–stimulated angiogenesis
but only partially affected the response to VEGF, whereas
antagonists of 
 
 
 
V
 
 
 
5 inhibited VEGF-, TGF
 
 
 
-, and
phorbol ester–induced angiogenesis. Cheresh and coworkers
further distinguished the pathways based on pharmaco-
logic susceptibility by demonstrating that inhibitors of
PKC (Friedlander et al., 1995) and the tyrosine kinase Src
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(Eliceiri et al., 1999) block VEGF- but not bFGF-induced
angiogenesis. This elegant but simple initial model of
growth factor–
 
 
 
V integrin coupling in angiogenesis has now
evolved into a complicated picture of intricate interactions
between growth factor receptors and integrins.
 
How do growth factors influence 
 
 
 
V integrin–mediated function?
 
Although they share few structural similarities and recognize
widely different ligands, growth factor receptors and inte-
grins elicit overlapping and, in some cases, additive intracel-
lular effects (Fig. 1). Synergy between integrins and growth
factors may occur in signaling complexes that cluster along
the cell surface (Plopper et al., 1995). Substantial evidence
points to both a physical and functional association between
integrins and VEGFR-2 that may be regulated by VEGF.
VEGF-induced tyrosine phosphorylated of VEGFR-2 and
cell proliferation is augmented in endothelial cells adherent
 
to the 
 
 
 
V
 
 
 
3 ligand vitronectin (Soldi et al., 1999). Af-
ter VEGF stimulation, tyrosine-phosphorylated VEGFR-2
coimmunoprecipitates with 
 
 
 
V
 
 
 
3 but not with integrin 
 
 
 
1
or 
 
 
 
5. Moreover, function-blocking antibodies to 
 
 
 
V and
 
 
 
3 inhibit VEGF-stimulated phosphorylation of VEGFR-2
and activation of the regulatory subunit of phosphatidyl-
inositol (PI) 3-kinase (Soldi et al., 1999). In CHO cells,
VEGFR-2 immunoprecipitates with 
 
 
 
V
 
 
 
3 but not with in-
tegrin 
 
 
 
5 (Borges et al., 2000) apparently through interac-
tions involving the extracellular domain of integrin 
 
 
 
3. De-
letion or alteration of the 
 
 
 
3 cytoplasmic domain does not
affect the association (Borges et al., 2000), suggesting that
the interaction does not require focal adhesion formation.
Growth factors modify the signals necessary for angiogene-
sis by altering the levels of integrins and their affinity for
ligands. The normally low endothelial expression of 
 
 
 
V
 
 
 
3
(Brooks et al., 1994a) can be upregulated by bFGF (Enen-
stein et al., 1992; Brooks et al., 1994a; Sepp et al., 1994) and
Figure 1. Cross-talk between growth factors and integrins in endothelial cells. VEGF binding to VEGFR-2 results in receptor dimerization 
and phosphorylation of specific tyrosine residues within the intracellular domain of the receptor. PLC , Sck, and VRAP (not depicted) all 
interact directly with VEGFR-2. The mechanism of activation of FAK, Src, MAPK, PI 3-kinase, and AKT by VEGFR-2 is less clearly understood. 
Recent work indicates that VEGF-mediated Src activation promotes FAK association with  V 5. The extracellular domain of  3 directs 
association of  V 3 with VEGFR-2. Engagement of either VEGFR-2 or  V 3 enhances the function of the reciprocal receptor. Binding of 
ECM proteins to  V 3 triggers phosphorylation of tyrosine residues located in the intracellular domain of the  3 chain and induces receptor 
clustering. Signaling molecules activated by ligation and/or clustering of  V 3 include FAK, Src, MAPK, PI 3-kinase, and Rho family members. 
Recent evidence suggests a role for an unidentified arachidonic acid (AA) metabolite in  V 3 activation of Rac. Phosphorylation of intracellular 
tyrosine residues of VEGFR-2 occurs in response to  V 3 ligation. The p53/bax pathway linked to apoptosis is suppressed by  V 3 engagement. 
The proapoptotic mediator caspase 8 may be activated by unligated  V 3-dependent membrane recruitment. Additionally, ligation of either 
 V 3 or  V 5 may influence the function of the reciprocal receptor. 
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VEGF (Senger et al., 1996) but not by TGF
 
 
 
 (Enenstein et
al., 1992; Sepp et al., 1994). The effects of individual growth
factors are integrin specific, since TGF
 
 
 
 heightens expres-
sion of the more abundant 
 
 
 
1 integrins, whereas bFGF’s ef-
fects are restricted to 
 
 
 
V
 
 
 
3. VEGF binding to VEGFR-2 ac-
tivates multiple integrins, including 
 
 
 
V
 
 
 
3, 
 
 
 
V
 
 
 
5, 
 
 
 
5
 
 
 
1,
and 
 
 
 
2
 
 
 
1, to enhance cell adhesion and migration (Byzova
et al., 2000). Particular tumors with high adhesive properties
display autocrine/paracrine integrin activation by VEGF
(Byzova et al., 2000). Finally, by activating the small GTP-
binding protein Rac, bFGF enhances Rac-dependent recruit-
ment of activated 
 
 
 
V
 
 
 
3 to lamellipodia where the receptor
directs cell migration (Kiosses et al., 2001).
 
What specific signaling pathways are coupled to 
 
 
 
V integrins?
 
Integrins play complex roles in controlling cell migration,
growth, differentiation, and apoptosis. Because of the redun-
dancy in the matrix proteins that are recognized by 
 
 
 
V
 
 
 
3 and
 
 
 
V
 
 
 
5, delineating their contribution to endothelial cell biol-
ogy has relied in large part on the use of inhibitors or matrix
molecules that appear to specifically target one or the other in-
tegrin. For example, Del1, an ECM protein and potent angio-
genic factor whose expression is restricted to endothelial cells
(Hidai et al., 1998), binds 
 
 
 
V
 
 
 
3 but not 
 
 
 
V
 
 
 
5 and triggers
focal adhesion formation and phosphorylation of focal adhe-
sion kinase (FAK), mitogen-activated protein kinase (MAPK)
(extracellular-regulated kinase), and Shc (Penta et al., 1999).
Arachidonic acid metabolism may also be critical to 
 
 
 
V
 
 
 
3-
dependent endothelial migration and angiogenesis. Dormond
et al. (2001) demonstrated recently that inhibition of cyclo-
oxygenase-2 prevents 
 
 
 
V
 
 
 
3-mediated endothelial cell spread-
ing, migration, and activation of Cdc 42 and Rac. These ef-
fects are overcome by prostaglandins, phorbol esters, and
constitutively active Cdc42 or Rac, suggesting that an uniden-
tified arachidonic acid metabolite may play a critical role in
 
 
 
V
 
 
 
3-mediated activation of Rac. In an angiogenesis model,
constitutively active Rac restored bFGF-induced angiogenesis
in the presence of cyclooxygenase-2 inhibition. This exciting
link between 
 
 
 
V
 
 
 
3, arachidonic acid metabolism, and angio-
genesis provides a novel mechanistic explanation for the ob-
servation that nonsteroid antiinflammatory agents protect
against cancer development and progression.
 
Several observations implicate 
 
 
 
V
 
 
 
3 in the control of cell
survival and proliferation. Administration of 
 
 
 
V
 
 
 
3 antibody
antagonists results in apoptosis of angiogenic but not quies-
cent vascular cells (Brooks et al., 1994b). Immobilization of
endothelial cells on plates coated with 
 
 
 
V
 
 
 
3 antibodies sup-
presses p53 and the bax cell death pathway, and inhibition of
 
 
 
V
 
 
 
3- but not 
 
 
 
V
 
 
 
5- or 
 
 
 
1-mediated cell adhesion acti-
vates p53 (Strömblad et al., 1996). Furthermore, 
 
 V antago-
nists appear to require the presence of p53 to inhibit retinal
neovascularization, in that p53-deficient mice are protected
from their effects (Strömblad et al., 2002). NF- B also plays
an important role in  V 3-mediated endothelial cell survival
after serum deprivation (Scatena et al., 1998). Moreover,
 V 3 antagonists block sustained endothelial MAPK activ-
ity in bFGF-treated chick chorioallantoic membranes. (Eli-
ceiri et al., 1998). A recent article demonstrated that endo-
thelial  V 3 elicits an “integrin-mediated death” pathway in
cells grown in an environment devoid of  V 3 ligands (Stu-
pack et al., 2001). Unligated  V 3 appears to initiate apop-
tosis by recruiting and activating caspase-8, an effect that is
mimicked by the proximal regions of the cytoplasmic do-
mains of both  3 and  1 but not  5. Limited calpain-
dependent cleavage of the cytoplasmic domain of  3 has been
observed early in the course of suspension-induced apoptosis
in endothelial cells (Meredith et al., 1998). Whether calpain
cleavage of  3 disrupts prosurvival signals generated by
 V 3 and/or facilitates the recruitment of caspase 8 in non-
adherent endothelial cells remains to be determined.
Several endogenous angiogenesis inhibitors may exert their
antiproliferative effects, in part, via  V 3 (see Table I for a
more complete list). Endothelial cell attachment to immobi-
lized endostatin (a 20-kd collagen COOH terminus cleavage
product) is mediated by  V 3,  5 1, and  V 5 (Rehn et
al., 2001); adhesion to immobilized tumstatin (NC1 domain
of the  3 chain of type IV collagen) is inhibited by antibodies
to  V 3,  1, and  6 (Maeshima et al., 2000). Both soluble
endostatin and tumstatin inhibit endothelial cell proliferation,
but endostatin elicits minimal apoptosis (2–5% cells), whereas
soluble tumstatin and tumstatin peptide derivatives induce
apoptosis at levels comparable to tumor necrosis factor– 
(Maeshima et al., 2001). Tumstatin also prevents  V 3-
dependent activation of FAK, PI 3-kinase, protein kinase B
(Akt), and cap-dependent protein synthesis in endothelial
Table I. Endogenous angiogenic proteins/proteolytic fragments that may exert their effects, at least in part, via integrins
Protein/proteolytic
fragment Effect
Integrin 
receptor(s) Nonintegrin receptor(s) Reference
Angiopoietins 1 and 2 Proangiogenic  5 1 Tie-2 Carlson et al., 2001
ANGPTL3 Proangiogenic  V 3 Camenisch et al., 2002
Angiostatin Antiangiogenic  V 3 ATP synthase, angiomotin Tarui et al., 2001
Cysteine-rich 61 
(CYR61, CCN1)
Proangiogenic/possible 
tumor suppressor
 V 3,  V 5, 
 6 1
Heparan sulfate proteoglycans Grzeszkiewicz et al., 2001
Del1 Proangiogenic  V 3 Hidai et al., 1998
Endostatin Antiangiogenic  V 3,  V 5, 
 2 1, a5 1
Glypican  (a heparan sulfate proteoglycan) Rehn et al., 2001
Thrombospondin-1 Antiangiogenic  V 3,  3 1, 
 4 1,  5 1
CD36, CD47 (integrin-associated protein) 
Low density lipoprotein 
receptor–related protein
Heparan sulfate proteoglycans
For review see Bornstein, 2001
Tumstatin Antiangiogenic  V 3,  6 1 Maeshima et al., 200020 The Journal of Cell Biology | Volume 158, Number 1, 2002
cells (Maeshima et al., 2002). The separate effects of endo-
statin and tumstatin on endothelial cell function may be me-
diated by distinct conformations assumed by  V 3 upon
binding these two ligands or may be the result of additional
signals generated by integrins other than  V 3 (e.g.,  V 5 in
the case of endostatin). The interaction of fibroblasts with
CYR61, an angiogenic matrix molecule that binds both
 V 5 and  V 3, demonstrates that  V integrins are able to
mediate discrete functions upon binding the same ligand:
CYR61 engagement of  V 5 promotes fibroblast migration,
but engagement of  V 3 is required to enhance bFGF-
induced proliferation (Grzeszkiewicz et al., 2001).
Although  V 3 appears to play a key role in regulating
endothelial cell survival, proliferation, and apoptosis,  V 5
has been linked to Src-dependent pathways stimulated by
VEGF. In stroke models where VEGF contributes to cere-
bral vascular permeability, brain edema, and injury (van
Bruggen et al., 1999), Src-deficient mice and wild-type mice
treated with Src inhibitors display reduced vascular perme-
ability and smaller infarct volumes (Paul et al., 2001). In a
recent article, Eliceiri et al. (2002) demonstrated that mice
deficient in integrin  5 are similarly protected from the ef-
fects of VEGF. More importantly, they elucidate the first
mechanistic link between VEGF-stimulated Src activity and
 V 5 by demonstrating that VEGF promotes Src-depen-
dent association of FAK with  V 5 in endothelial cells.
VEGF stimulation dramatically increases the coimmunopre-
cipitation of FAK with  V 5, an event that involves Src-
mediated phosphorylation of FAK at tyrosine residue 861.
The effects are selective in that VEGF does not alter the con-
stitutive association of  V 3 and FAK, and bFGF does not
promote   V 5–FAK complex formation. These findings
provide a novel mechanism for VEGF regulation of  V 5
signaling, which places Src upstream rather than downstream
of FAK activation and integrin association.
Clearly,  V integrin-dependent events do not occur in iso-
lation, and other endothelial integrins may influence angio-
genic events. Additionally, integrin cross-talk, the phenom-
ena in which ligation of one integrin influences the behavior
of a second integrin on the same cell, may regulate endothe-
lial   V 3 function. Antagonists of integrin  5 1, which
block growth factor- and tumor-induced angiogenesis, in-
hibit  V 3-promoted human umbilical vein endothelial cell
migration and focal contact formation via a protein kinase
A–dependent pathway (Kim et al., 2000). Interestingly, in
the same cells  V 3 antagonists have been shown to block
 5 1-mediated migration (Simon et al., 1997), suggesting
that endothelial integrin cross-talk may be bidirectional.
What has target gene deletion in mice revealed about 
the role of  V integrins in angiogenesis?
Studies in mice with targeted gene deletions of either  V,
 3, or  5 were initially less informative than anticipated
with regard to the role of these integrins in angiogenesis.
Embryos deficient in  V develop normally until E9.5 and
have unimpaired vasculogenesis and angiogenesis in many
organs. Approximately 80% of the embryos die, apparently
as the result of placental defects. The mice that survive suffer
lethal intracranial and intestinal hemorrhage (Bader et al.,
1998). Mice lacking either integrin  3 (Hodivala-Dilke et
al., 1999) or  5 (Huang et al., 2000) undergo normal angio-
genesis, and the pattern of retinal neovascularization in  3-
null mice is indistinguishable from that in wild-type mice.
In a follow-up to the original characterization of the  3
 / 
mice, Hodivala-Dilke’s group reported that tumors grown
in  3
 /  mice or in mice with a combined deficiency of  3
and  5 are larger in size and display enhanced angiogenesis
(Reynolds et al., 2002). They observed an augmented angio-
genic response to VEGF in  3
 /  endothelial cells that cor-
responded to increased levels of VEGFR-2, suggesting that
upregulation of VEGF signaling may enhance tumor angio-
genesis in  3-deficient mice. Both Eliceiri’s latest work and
recent studies in the  3
 /  mice establish that a closer exam-
ination of the  5
 /  and  3
 /  mice is warranted and may
reveal fascinating information about the relationship be-
tween integrins and growth factors.
Bringing together  V integrins, growth factors, 
and angiogenesis
A wealth of data indicates that growth factor receptors and  V
integrins interact physically and functionally to generate the
signals necessary for angiogenesis (Fig. 1). Many of the re-
sponses modulated by  V 3 are linked to proliferative and/or
apoptotic pathways, whereas Eliceiri et al. (2002) convinc-
ingly tie  V 5 with pathways involving FAK and Src. How-
ever, several questions remain. The chief question is how to
resolve the discrepancies in the antiangiogenic effects of anti-
body and small molecule  V 3 and/or  V 5 inhibitors with
the apparent normal developmental angiogenesis and en-
hanced tumor angiogenesis in the  3- and combined  3/ 5-
deficient mice. Does compensatory upregulation of VEGFR-
2 account for normal developmental angiogenesis in the  3
 / 
mice? In the absence of  V 3, does VEGF enhance the affin-
ity of alternate compensatory integrins? Or, do  V 3 antago-
nists mediate their effects through distinct signaling mecha-
nisms such as by recruitment of caspase 8 with subsequent
activation of apoptotic pathways or by transdominant integrin
inhibition? Do growth factors paradoxically induce endothe-
lial cell susceptibility to  V 3 antagonists by upregulating
receptor levels? One hypothesis that reconciles the antian-
giogenic effects of  V inhibitors with enhanced tumor an-
giogenesis in mice lacking  V 3 is the receptor can either
promote or inhibit endothelial cell survival/proliferation de-
pending on the presence of external stimuli and the composi-
tion of the ECM. Thus, under certain conditions  V 3 may
assume a conformation that generates signals to maintain en-
dothelial cells in a quiescent state. Tumor-induced alterations
in growth factors and matrix may shift the conformation of,
and signaling pathways generated by,  V 3. In this scenario,
the lack of basal  V 3-mediated endothelial inhibition in
 3
 /  mice could result in enhanced proliferation in response
to VEGF or other factors. Treatment with  V antagonists
may maintain the initial  V 3-mediated inhibitory signals
and/or may trigger signals for apoptosis or transdominant in-
hibition of other integrins. Although investigations in this
field have made rapid progress, the complexities of the inte-
grin–growth factor nexus have not been fully revealed.
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